Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ATG7 | O95352 | 6/20 | 0.41 |
| ▸ | NAE1 | Q13564 | 3/20 | 0.38 |
| ▸ | UBA3 | Q8TBC4 | 3/20 | 0.38 |
| ▸ | UBA6 | A0AVT1 | 1/20 | 0.38 |
| ▸ | UBA7 | P41226 | 1/20 | 0.38 |
| ▸ | SAE1 | Q9UBE0 | 1/20 | 0.38 |
| ▸ | SLC29A1 | Q99808 | 2/20 | 0.37 |
| ▸ | ADORA3 | P0DMS8 | 2/20 | 0.37 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.37 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.37 |
| ▸ | CA1 | P00915 | 1/20 | 0.37 |
| ▸ | CA2 | P00918 | 1/20 | 0.37 |
| ▸ | CA4 | P22748 | 1/20 | 0.37 |
| ▸ | CA9 | Q16790 | 1/20 | 0.37 |
| ▸ | NT5E | P21589 | 1/20 | 0.35 |
| ▸ | SLC5A2 | P31639 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL866287 | 1.00 | ATG7 (0.41) | ATG7NAE1UBA3UBA6UBA7 | |
| SCHEMBL866952 | 0.82 | AURKA (0.49) | ATG7NAE1UBA3UBA6UBA7 | |
| SCHEMBL865137 | 0.82 | AURKA (0.49) | ATG7NAE1UBA3UBA6UBA7 | |
| SCHEMBL866212 | 0.77 | AURKA (0.42) | ATG7NAE1UBA3UBA6UBA7 | |
| SCHEMBL865269 | 0.77 | AURKA (0.42) | ATG7NAE1UBA3UBA6UBA7 | |
| SCHEMBL867144 | 0.76 | ATG7 (0.49) | ATG7 | |
| SCHEMBL867383 | 0.76 | ATG7 (0.49) | ATG7 | |
| SCHEMBL867352 | 0.75 | ATG7 (0.41) | ATG7NAE1UBA3UBA6UBA7 | |
| SCHEMBL10185764 | 0.75 | ATG7 (0.41) | ATG7NAE1UBA3UBA6UBA7 | |
| SCHEMBL866807 | 0.75 | ATG7 (0.41) | ATG7NAE1UBA3UBA6UBA7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120077814-A1 | SULFONAMIDE, SULFAMATE, AND SULFAMOTHIOATE DERIVATIVES | WANG ZHONG (US) | 2012-03-29 | — | — | US | claimed |
| US-20120077814-A1 | SULFONAMIDE, SULFAMATE, AND SULFAMOTHIOATE DERIVATIVES | WANG ZHONG (US) | 2012-03-29 | — | — | US | disclosed |
| US-20120077814-A1 | SULFONAMIDE, SULFAMATE, AND SULFAMOTHIOATE DERIVATIVES | WANG ZHONG (US) | 2012-03-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120077814-A1 | SULFONAMIDE, SULFAMATE, AND SULFAMOTHIOATE DERIVATIVES | NEDD8, NAE1, UBA3 | ATG7 798/4885NAE1 2/4885UBA3 3/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.